[1]
|
Gwee, K.A., Goh, V., Lima, G. and Setia, S. (2018) Coprescribing Proton-Pump Inhibitors with Non-Steroidal An-ti-Inflammatory Drugs: Risks versus Benefits. Journal of Pain Research, 11, 361-374.
https://doi.org/10.2147/JPR.S156938
|
[2]
|
韩俊萍, 李嘉琪, 吴跃章, 等. CYP2C9基因多态性对非甾体抗炎药代谢及其消化道出血的影响[J]. 药学与临床研究, 2018, 26(1): 35-39.
|
[3]
|
Masso Gonzalez, E.L., Patrignani, P., Tacconelli, S., et al. (2010) Variability among Nonsteroidal Antiinflammatory Drugs in Risk of Upper Gastrointestinal Bleeding. Arthritis & Rheumatism, 62, 1592-1601.
https://doi.org/10.1002/art.27412
|
[4]
|
和芳, 张泰昌. 老年人非甾体抗炎药相关上消化道出血的临床特征[J]. 中华消化内镜杂志, 2006, 23(1): 56-58.
|
[5]
|
Vergara, M., Catalán, M., Gisbert, J.P., et al. (2005) Meta-Analysis: Role of Helicobacter pylori Eradication in the Prevention of Peptic Ulcer in NSAID Users. Alimentary Pharmacology & Therapeutics, 21, 1411-1418.
https://doi.org/10.1111/j.1365-2036.2005.02444.x
|
[6]
|
Melcarne, L., García-Iglesias, P. and Calvet, X. (2016) Management of NSAID-Associated Peptic Ulcer Disease. Expert Review of Gastroenterology & Hepatology, 10, 723-733. https://doi.org/10.1586/17474124.2016.1142872
|
[7]
|
Sostres, C., Carrera-Lasfuentes, P., Benito, R., et al. (2015) Peptic Ulcer Bleeding Risk. The Role of Helicobacter pylori Infection in NSAID/Low-Dose Aspirin Users. American Journal of Gastroenterology, 110, 684-689.
https://doi.org/10.1038/ajg.2015.98
|
[8]
|
马师洋, 陈旻湖. 非甾体抗炎药胃黏膜损害的危险因素与预防[J]. 新医学, 2008, 39(3): 190-192.
|
[9]
|
中华消化杂志编委会. 消化性溃疡病诊断与治疗规范(2013年, 深圳) [J]. 中华消化杂志, 2014, 34(2): 73-76.
|
[10]
|
徐海栋, 刘博, 李兆申. NSAIDs相关性消化性溃疡研究进展[J]. 国外医学消化系疾病分册, 2003, 23(2): 88-90.
|
[11]
|
许淑华. 非甾体抗炎药所致中老年人急性胃黏膜病变32例临床分析[J]. 中国现代医生, 2009, 47(25): 174-190.
|
[12]
|
Lanza, F.L., Chan, F.K., Quigley, E.M., et al. (2009) Guidelines for Prevention of NSAID-Related Ulcer Complications. American Journal of Gastroenterology, 104, 728-738.
|
[13]
|
Bommu, U.D., Konidala, K.K., Pamanji, R., et al. (2017) Structural Probing, Screening and Struc-ture-Based Drug Repositioning Insights into the Identification of Potential COX-2 Inhibitors from Selective Coxibs. Interdisciplinary Sciences, 13, 278-289.
|
[14]
|
Dulce, H.J.C., Bruno, H.S. and Mariza, A.M. (2017) Role of Meloxicam as a Selective Inhibitor of COX-2 in the Inhibition of Ehrlich Solid Tumor Growth. African Journal of Pharmacy and Pharmacology, 11, 295-299.
https://doi.org/10.5897/AJPP2017.4780
|
[15]
|
田文武, 王心怡, 刘丹, 等. 非甾体抗炎药致胃肠损伤机制的研究进展[J]. 生命的化学, 2018, 38(2): 250-254.
|
[16]
|
Kangwan, N., Park, J.M. and Hahm, K.B. (2014) Development of GI-Safe NSAID; Progression from the Bark of Willow Tree to Modern Pharmacology. Current Opinion in Pharmacology, 19, 17-23.
https://doi.org/10.1016/j.coph.2014.06.003
|
[17]
|
Yarla, N.S., Bishayee, A., Sethi, G., et al. (2016) Targeting Arachidonic Acid Pathway by Natural Products for Cancer Prevention and Therapy. Seminars in Cancer Biology, 40-41, 48-81. https://doi.org/10.1016/j.semcancer.2016.02.001
|
[18]
|
Levi, S., Goodlad, R.A., Lee, C.Y., et al. (1990) Inhibitory Effect of Non-Steroidal Anti-Inflammatory Drugs on Mucosal Cell Proliferation Associated with Gastric Ulcer Healing. The Lancet, 336, 840-843.
https://doi.org/10.1016/0140-6736(90)92341-E
|
[19]
|
Saunders, F.R., Hughes, A. and Wallace, H.M. (2008) Investigating the Effects of NSAIDs on the Expression of Regulatory Components of the Polyamine Pathway. Toxicology, 253, 22-23. https://doi.org/10.1016/j.tox.2008.07.028
|
[20]
|
Mizushima, T. (2015) Development of NSAIDs with Lower Gastric Side Effect. Yakugaku Zasshi, 28, 100-104.
|
[21]
|
陈旻湖, 毛苇. 非甾体类抗炎药相关性胃十二指肠损伤的防治[J]. 中国实用内科杂志, 2007, 27(11): 841-843.
|
[22]
|
江小云. 非甾体类抗炎药致胃肠道黏膜损害的临床特点[J]. 临床和实验医学杂志, 2011, 10(10): 739-740.
|
[23]
|
刘文忠. 日本《消化性溃疡循证临床实践指南(2015年)》解读[J]. 胃肠病学, 2016, 21(3): 129-137.
|
[24]
|
李东升, 郑辉利, 刘刚. 非甾体抗炎药物纳米递送系统研究进展[J]. 药学进展, 2021, 45(4): 243-253.
|
[25]
|
Lanas, A. and Sostres, C. (2014) PPI Therapy. The Small Bowel, Low-Dose Aspirin and PPIs—Should We Be Concerned? Nature Reviews Gastroenterology & Hepatology, 11, 458-4460. https://doi.org/10.1038/nrgastro.2014.120
|
[26]
|
罗洋, 朱兰平, 雷月, 等. 非甾体类抗炎药相关小肠损伤的研究进展[J]. 世界华人消化杂志, 2021, 29(20): 1191-1200.
|
[27]
|
中华人民共和国国家卫生健康委员会. 质子泵抑制剂临床应用指导原则(2020年版) [J]. 中国实用乡村医生杂志, 2021, 28(1): 1-9.
|
[28]
|
中华消化杂志编委会. 消化性溃疡病的规范诊治策略[J]. 中国社区医师, 2012, 28(42): 16.
|
[29]
|
朱兰平, 赵经文, 陈鑫, 等. PPIs使用与NSAIDs相关小肠损伤: 如何平衡风险和获益[J]. 世界华人消化杂志, 2018, 26(22): 1334-1339.
|
[30]
|
谢颖聪. NSAIDs相关消化性溃疡70例临床分析[D]: [硕士学位论文]. 大连: 大连医科大学, 2018.
|
[31]
|
刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 中国实用内科杂志, 2017, 37(6): 509-524.
|
[32]
|
彭飞, 黄福斌. 非甾体类抗炎药相关性溃疡中医研究[J]. 吉林中医药, 2011, 31(9): 826-827.
|
[33]
|
张锡纯. 《重订医学衷中参西录》(上) [M]. 北京: 人民卫生出版社, 2006: 136.
|
[34]
|
熊国卫, 姜树民. 姜树民辨治非甾体抗炎药引起胃黏膜损伤经验[J]. 上海中医药杂志, 2008, 42(4): 13-14.
|
[35]
|
徐景藩, 徐丹华, 罗斐和. 徐景藩脾胃病经验辑要[M]. 南京: 江苏科学技术出版社, 1999: 91-92.
|
[36]
|
郑新春, 朱生樑. 朱生樑辨治非甾体类抗炎药相关性胃病经验[J]. 中国医药导报, 2020, 17(20): 156-159.
|
[37]
|
张丽颖, 唐旭东. 非甾体抗炎药消化道黏膜损伤的中医药治疗探讨[J]. 北京中医药, 2013, 32(5): 355-357.
|
[38]
|
邹兰亭. 加味五七散治疗NSAIDs相关性胃溃疡的临床观察及对PGE2、IL-1、TNF-α的影响[D]: [博士学位论文]. 南京: 南京中医药大学, 2017.
|
[39]
|
王颖颖, 张烁. 中医药治疗非甾体消炎药相关性胃肠损伤研究进展[J]. 浙江中西医结合杂志, 2020, 30(10): 862-864.
|
[40]
|
傅智敏. 健脾消瘀汤治疗老年人非甾体药物胃肠道损伤[J]. 浙江中西医结合杂志, 2008, 18(3): 156-157.
|
[41]
|
张晗, 刘金苓, 程晓云. 健脾益胃汤治疗非甾体抗炎药相关性胃病的临床观察[J]. 中医药通报, 2014, 13(4): 48-50.
|
[42]
|
李建平, 李建军, 司淑伟. 加味香砂六君子汤治疗非甾体类抗炎药相关性溃疡中虚气滞证疗效观察[J]. 现代中西医结合杂志, 2015, 24(22): 2431-2433.
|
[43]
|
苏艳秋, 毛俊青, 许向前, 等. 孙晓娜教授运用健脾活血汤治疗非甾体消炎药相关性胃病经验[J]. 中医研究, 2020, 33(7): 46-48.
|
[44]
|
龚诚. 益气活血方预防NSAIDs胃黏膜损伤临床观察[J]. 山西中医, 2013, 29(3): 10-12.
|
[45]
|
张卫平, 葛惠男, 郭金伟. 益气活血方对消化性溃疡愈合质量及复发的影响[J]. 中国中西医结合杂志, 2009, 29(12): 1081-1084.
|
[46]
|
陈建勇, 潘峰. 健胃合剂对非甾体消炎药致胃黏膜损伤大鼠胃黏膜血流、6-keto-PGF1α和TXB2的影响[J]. 中国中医药科技, 2008, 15(4): 255-256
|
[47]
|
张耀人. 健脾益气方调控NSAIDs胃黏膜损伤COX-2信号中CREB蛋白通路转导研究[D]: [博士学位论文]. 广州: 广州中医药大学, 2014.
|
[48]
|
钟明道. 健中愈疡片调控NSAIDs胃黏膜损伤COX-2信号中NF-κβ通路转导的研究[D]: [博士学位论文]. 广州: 广州中医药大学, 2014.
|
[49]
|
王媛媛, 郑亮. 五七散治疗非甾体类抗炎药相关性胃溃疡的临床研究[J]. 中医药导报, 2015, 21(13): 17-20.
|
[50]
|
王培. 加味五七散治疗非甾体类抗炎药相关性胃溃疡对大鼠胃黏膜P38MAPK信号通路表达的影响[D]: [硕士学位论文]. 南京: 南京中医药大学, 2016.
|